The RE-DUAL PCI trial demonstrated a lower risk of bleeding among those receiving dual therapy with dabigatran and a P2Y12 inhibitor compared to those receiving triple therapy with warfarin (P2Y12 inhibitor) and aspirin [16]. POINEER AF-PCI trial showed that low-dose rivaroxaban with a DAPT for 6-12 months was associated with low risk of clinically significant bleeding than the therapy with VKA plus DAPT [15]. Here, P2RY12 is linked to atrial fibrillation.